INCA - Instituto Nacional de Câncer

Rio de Janeiro 20231-050

2 studies enrolling now · 8 studies all time

What they study most

Acute Myeloid Leukemia, Biliary Tract Cancer, Cervical Cancer, Cholangiocarcinoma, First Line Non-Small Cell Lung Cancer, Gallbladder Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Head and Neck Cancer, Leukemia, Non-small Cell Lung Cancer, Small Cell Lung Cancer

Studies at this site

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission — Recruiting now
• RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer — Stopped early
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) — Stopped early
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) — Completed
• Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer — Completed
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC — Stopped early